NCT05546879View on ClinicalTrials.gov

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

NP137

NP137 at 9 or 14 mg/kg IV will be administered every 21 days.

DRUG

Atezolizumab

Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle

DRUG

Bevacizumab

Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle

Trial Locations (1)

38043

RECRUITING

CHU de GRENOBLE ALPES, Grenoble

Sponsors

Collaborators (1)

NETRIS Pharma
All Listed Sponsors
collaborator

NETRIS Pharma

INDUSTRY

lead

University Hospital, Grenoble

OTHER

NCT05546879 - Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC | Biotech Hunter | Biotech Hunter